181 related articles for article (PubMed ID: 22842455)
1. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.
Yamauchi T; Nakamura N; Hiramoto M; Yuri M; Yokota H; Naitou M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Kobori M; Katou M; Tawara S; Kawabata S; Furuichi K
Biochem Biophys Res Commun; 2012 Sep; 425(4):711-6. PubMed ID: 22842455
[TBL] [Abstract][Full Text] [Related]
2. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin.
Nakamura N; Yamauchi T; Hiramoto M; Yuri M; Naito M; Takeuchi M; Yamanaka K; Kita A; Nakahara T; Kinoyama I; Matsuhisa A; Kaneko N; Koutoku H; Sasamata M; Yokota H; Kawabata S; Furuichi K
Mol Cell Proteomics; 2012 Jul; 11(7):M111.013243. PubMed ID: 22442257
[TBL] [Abstract][Full Text] [Related]
3. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
4. p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A.
Zhu Z; Zhao X; Zhao L; Yang H; Liu L; Li J; Wu J; Yang F; Huang G; Liu J
Oncogene; 2016 Mar; 35(11):1399-410. PubMed ID: 26148231
[TBL] [Abstract][Full Text] [Related]
5. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
Cheng CC; Chou KF; Wu CW; Su NW; Peng CL; Su YW; Chang J; Ho AS; Lin HC; Chen CG; Yang BL; Chang YC; Chiang YW; Lim KH; Chang YF
Lung Cancer; 2018 Feb; 116():80-89. PubMed ID: 29413056
[TBL] [Abstract][Full Text] [Related]
6. p54nrb/NONO regulates cyclic AMP-dependent glucocorticoid production by modulating phosphodiesterase mRNA splicing and degradation.
Lu JY; Sewer MB
Mol Cell Biol; 2015 Apr; 35(7):1223-37. PubMed ID: 25605330
[TBL] [Abstract][Full Text] [Related]
7. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
[TBL] [Abstract][Full Text] [Related]
9. Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistance.
Li S; Kuhne WW; Kulharya A; Hudson FZ; Ha K; Cao Z; Dynan WS
Nucleic Acids Res; 2009 Nov; 37(20):6746-53. PubMed ID: 19759212
[TBL] [Abstract][Full Text] [Related]
10. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
[TBL] [Abstract][Full Text] [Related]
11. Proteomic identification of PSF and p54(nrb) as TopBP1-interacting proteins.
Kuhnert A; Schmidt U; Monajembashi S; Franke C; Schlott B; Grosse F; Greulich KO; Saluz HP; Hänel F
J Cell Biochem; 2012 May; 113(5):1744-53. PubMed ID: 22213094
[TBL] [Abstract][Full Text] [Related]
12. YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.
Sasaki R; Ito S; Asahi M; Ishida Y
Leuk Res; 2015 Dec; 39(12):1473-9. PubMed ID: 26547260
[TBL] [Abstract][Full Text] [Related]
13. The mitotic phosphorylation of p54(nrb) modulates its RNA binding activity.
Bruelle C; Bédard M; Blier S; Gauthier M; Traish AM; Vincent M
Biochem Cell Biol; 2011 Aug; 89(4):423-33. PubMed ID: 21819346
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of P54(nrb) /NonO correlates with collagen deposition and fibrosis in human aortic dissection.
Ren Z; Wang Z; Hu Z; Hu X; Zhang H; Wu H; Hu R; Liu H
Histopathology; 2014 Oct; 65(4):570-80. PubMed ID: 24720418
[TBL] [Abstract][Full Text] [Related]
16. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.
Xia H; Chen J; Shi M; Deivasigamani A; Ooi LL; Hui KM
Oncotarget; 2015 Mar; 6(8):5990-6000. PubMed ID: 25714025
[TBL] [Abstract][Full Text] [Related]
17. YM155 induces EGFR suppression in pancreatic cancer cells.
Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW
PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871
[TBL] [Abstract][Full Text] [Related]
18. YBX1 is a modulator of MIA/CD-RAP-dependent chondrogenesis.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
PLoS One; 2013; 8(12):e82166. PubMed ID: 24349210
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
20. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
